Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2018-05-07

Clinical Trial Update: Lovaza Therapy of Peripheral Arterial Disease [NA]

View source ↗

Summary

A clinical trial evaluating Lovaza (omega-3-acid ethyl esters) for peripheral artery disease has been withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LOVAZA (OMEGA-3-ACID ETHYL ESTERS)

Snippet

Sponsor: University of Virginia | Conditions: Peripheral Artery Disease | NA | Status: WITHDRAWN